SAN FRANCISCO, March 8, 2019 /PRNewswire/ -- Audentes
Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company
focused on developing and commercializing innovative gene therapy
products for patients living with serious, life-threatening rare
diseases, announced it has granted equity awards on March 7,
2019, that were previously approved by the Compensation Committee
of its Board of Directors under the Audentes Therapeutics, Inc.
2018 Equity Inducement Plan, as a material inducement to employment
to six individuals hired by Audentes in February 2019. The
equity awards were approved in accordance with Nasdaq Listing Rule
5635(c)(4).
The employees received, in the aggregate, options to purchase
14,600 shares of Audentes common stock. The options have an
exercise price of $32.61 per share, which is equal to the
closing price of Audentes common stock on March 7, 2019.
One-fourth of the shares underlying each employee's option will
vest on the one year anniversary of his or her date of hire and
thereafter 1/48th of the shares underlying each employee's option
will vest monthly, such that the shares underlying the option
granted to each employee will be fully vested on the fourth
anniversary of his or her date of hire, in each case, subject to
each such employee's continued employment with Audentes on such
vesting dates.
Two employees also received, in the aggregate, 600 restricted
stock units ("RSUs"). One-fourth of the RSUs will vest on
March 5, 2020 and 1/16th of the RSUs
will vest on each of June 5,
September 5, December 5 and March
5 thereafter, such that the RSUs will be fully vested on the
fourth anniversary of March 5, 2019,
in each case, subject to each such employee's continued employment
with Audentes on such vesting dates.
About Audentes Therapeutics, Inc.
Audentes
Therapeutics (Nasdaq: BOLD) is a biotechnology company focused on
developing and commercializing innovative gene therapy products for
patients living with serious, life-threatening rare diseases.
We are currently conducting Phase 1/2 clinical studies of our lead
product candidates, AT132 for the treatment of X-linked Myotubular
Myopathy (XLMTM), and AT342 for the treatment of Crigler-Najjar
syndrome. We have two additional product candidates in
development, including AT845 for the treatment of Pompe disease,
and AT307 for the treatment of the CASQ2 subtype of
catecholaminergic polymorphic ventricular tachycardia
(CASQ2-CPVT). We are a focused, experienced and passionate
team committed to forging strong, global relationships with the
patient, research and medical communities.
For more information regarding Audentes, please visit
www.audentestx.com.
Audentes Contacts:
Investor Contact:
Andrew Chang
415.818.1033
achang@audentestx.com
Media Contact:
Katie Hogan
415.951.3398
khogan@audentestx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/audentes-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-300809091.html
SOURCE Audentes Therapeutics, Inc.